OncoMatch/Clinical Trials/NCT04111978
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Is NCT04111978 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Letrozole 2.5mg for ovarian neoplasm epithelial.
Treatment: Letrozole 2.5mg — The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo. The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: ESR1 expression ≥ 1% (≥ 1%)
Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial)
Disease stage
Required: Stage II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: platinum-based chemotherapy — neoadjuvant or adjuvant
At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed)
Must have received: debulking surgery — interval or primary
(Interval-) debulking performed
Cannot have received: chemotherapy
< 4 cycles of chemotherapy in total
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify